PLEASE TELL US A LITTLE ABOUT YOURSELF SO THAT WE CAN DISPLAY THE MOST
APPROPRIATE CONTENT TO YOU:

This site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about cookies used on Trustnet and how you can manage them, see our Privacy and Cookie Policy.

By clicking "I Agree" below, you acknowledge that you accept our Privacy Policy and Terms of Use.

For more information Click here

Login

Register

It's look like you're leaving us

What would you like us to do with the funds you've selected

Show me all my options Forget them Save them
Customise this table
Share   Print      RSS

Advanced Oncotherapy (AVO)

Advanced Oncotherapy

Result of AGM and Directorate Changes
RNS Number : 5135U
Advanced Oncotherapy PLC
29 July 2020
 

29 July 2020

 

ADVANCED ONCOTHERAPY PLC

 

("Advanced Oncotherapy" or the "Company")

 

Result of AGM and Directorate Changes

 

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that at the Annual General Meeting held earlier today, all resolutions were passed on a poll. The results of the proxy voting for the AGM are set out below:

 

Resolution

Total votes For1

% of votes cast2

Total Votes Against

% of votes cast2

Votes Withheld3

1. To receive the audited financial statements and the Auditor's and Directors' reports for the year ended 31st December 2019.

172,734,768

99.95

90,000

0.05

3,013

2. To re-appoint Michael Bradfield as a Director of the Company.

172,734,286

99.95

93,330

0.05

165

3. To re-appoint Hans von Celsing as a Director of the Company.

172,734,286

99.95

93,330

0.05

165

4. To re-appoint Prof. Steve Myers as a Director of the Company.

172,824,286

99.99

830

0.01

2,665

5. To re-appoint Dr Nick Plowman as a Director of the Company.

172,824,286

99.99

830

0.01

2,665

6. To re-appoint Nicolas Serandour as a Director of the Company.

172,824,286

99.99

830

0.01

2,665

7. To re-appoint Dr Michael Sinclair as a Director of the Company.

172,826,786

99.99

995

0.01

0

8. To re-appoint Dr Enrico Vanni as a Director of the Company.

172,736,786

99.95

90,830

0.05

165

9. To re-appoint Renhua Zhang as a Director of the Company.

172,823,286

99.99

1,830

0.01

2,665

10. To re-appoint RPG Crouch Chapman LLP as Auditors of the Company to hold office until the conclusion of the next AGM at which accounts are laid before the Company

172,826,951

100.00

0

0.00

830

11. To authorise the Directors to determine the remuneration of the

Auditors.

172,823,451

99.90

3,500

0.01

830

12. Authority to allot shares

172,822,517

99.99

5,264

0.01

0

13. Authority to disapply pre-emption rights

172,703,050

99.93

124,566

0.07

165

 

Notes

 

1.  Any proxy votes that were at the discretion of the Chairman are included in the "Total Votes For" each resolution

2.  Percentage of votes cast excludes Votes Withheld

3.  Votes Withheld are not votes in law and do not count in the number of votes counted for or against a resolution

 

Directorate Changes  

 

As announced on 8 June 2020, Mr Gabriel Urwitz, Mr Peter Sjöstrand, Mr Chunlin "Allen" Han and Dr Yuelong Huang (all Non-Executive Directors of the Company) did not seek re-election at the Company's AGM. Accordingly, these directors have now stepped down from the Board with immediate effect and consequently the size of the Board has decreased from 12 to 8 people.

 

- ENDS -

 

Advanced Oncotherapy plc

www.avoplc.com

Dr. Michael Sinclair, Executive Chairman

Tel: +44 (0) 20 3617 8728

Nicolas Serandour, CEO




Allenby Capital Limited (Nomad & Broker)


Nick Athanas / Liz Kirchner (Corporate Finance)

Amrit Nahal / Matt Butlin (Sales & Broking)

Tel: +44 (0) 20 3328 5656



FTI Consulting (Financial PR & IR)

advancedoncotherapy@fticonsulting.com

Simon Conway / Rob Winder

Tel: +44 (0) 20 3727 1000

 

 

Notes for Editors

 

About Advanced Oncotherapy Plc www.avoplc.com

 

Advanced Oncotherapy, a UK headquartered company with offices in London, Geneva, The Netherlands and in the USA, is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM," based in Geneva, focuses on the development of a proprietary proton accelerator called, Linac Image Guided Hadron Technology (LIGHT). LIGHT's compact configuration delivers proton beams in a way that facilitates greater precision and electronic control.

 

Advanced Oncotherapy will offer healthcare providers affordable systems that will enable them to treat cancer with innovative technology as well as expected lower treatment-related side effects.

 

Advanced Oncotherapy continually monitors the market for any emerging improvements in delivering proton therapy and actively seeks working relationships with providers of these innovative technologies. Through these relationships, the Company will remain the prime provider of an innovative and cost-effective system for particle therapy with protons.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
RAGKZGZNFLGGGZM
Data provided by FE fundinfo. Care has been taken to ensure that the information is correct, but FE fundinfo neither warrants, represents nor guarantees the contents of information, nor does it accept any responsibility for errors, inaccuracies, omissions or any inconsistencies herein. Past performance does not predict future performance, it should not be the main or sole reason for making an investment decision. The value of investments and any income from them can fall as well as rise.

You are currently using an old browser which will not be supported by Trustnet after 31/07/2016. To ensure you benefit from all features on the site, please update your browser.   Close